The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Tilmicosin     (2R,3R,9R,11R,12R,13S,14R)- 12-[(2S,3R,4S...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Tilmicosin


Psychiatry related information on Tilmicosin


High impact information on Tilmicosin


Chemical compound and disease context of Tilmicosin


Biological context of Tilmicosin


Anatomical context of Tilmicosin


Associations of Tilmicosin with other chemical compounds


Gene context of Tilmicosin

  • Compared with 5mug/mL, tilmicosin and tylosin concentrations of 10mug/mL and 20mug/mL significantly decreased the production of 6-keto-prostaglandin F(1alpha) (6-keto-PGF(1alpha)), PGE(2), NO, tumour necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6, and increased IL-10 production [23].
  • Erythromycin and tilmicosin were found to be relatively less effective inhibitors of CYP450 activity in microsomes, and their activity in the bovine CYP3A4 expressing cell line was relatively weak [24].
  • Finally, the mechanisms of tilmicosin-induced PMN apoptosis were examined by assessing the effects of tilmicosin on surface Fas expression on PMN [25].
  • Tilmicosin uptake was observed to increase lysosomal enzyme (acid phosphatase, lysozyme, avidin, and beta-glucuronidase) production [14].
  • Rectal temperatures, neutrophil infiltration, phagocytosis, oxidative functions, membrane leakage, and soluble TNF-alpha concentrations were not significantly affected by tilmicosin [26].

Analytical, diagnostic and therapeutic context of Tilmicosin

  • Determination of tilmicosin in ovine milk using high-performance liquid chromatography [2].
  • Tilmicosin is determined using reversed-phase HPLC and ultraviolet (UV) detection at 280 nm [2].
  • Tilmicosin, a new macrolide antibiotic, 20-deoxo-20-(3,5-dimethylpiperidin-l-yl)desmycosin, formerly identified as EL-870, has been evaluated in three experiments as a single subcutaneous injection at dosages of 10, 20 or 30 mg/kg for the treatment of naturally occurring pneumonia in neonatal calves [27].
  • Severity of clinical disease was significantly (P < 0.03) less for the tilmicosin-treated calves on days 2 and 3 after treatment [28].
  • Bacterial isolates obtained from swine with various clinical diseases were tested for susceptibility to tilmicosin by minimum inhibitory concentration (MIC) and Kirby-Bauer disk diffusion tests using National Committee on Clinical Laboratory Standards methodology [29].


  1. Tilmicosin induces apoptosis in bovine peripheral neutrophils in the presence or in the absence of Pasteurella haemolytica and promotes neutrophil phagocytosis by macrophages. Chin, A.C., Lee, W.D., Murrin, K.A., Morck, D.W., Merrill, J.K., Dick, P., Buret, A.G. Antimicrob. Agents Chemother. (2000) [Pubmed]
  2. Determination of tilmicosin in ovine milk using high-performance liquid chromatography. Parker, R.M., Patel, R.K. The Analyst. (1994) [Pubmed]
  3. Efficacy dose determination study of tilmicosin phosphate in feed for control of pneumonia caused by Actinobacillus pleuropneumoniae in swine. Moore, G.M., Mowrey, D.H., Tonkinson, L.V., Lechtenberg, K.F., Schneider, J.H. Am. J. Vet. Res. (1996) [Pubmed]
  4. Efficacy of tilmicosin in the control of experimental Mycoplasma gallisepticum infection in chickens. Kempf, I., Reeve-Johnson, L., Gesbert, F., Guittet, M. Avian Dis. (1997) [Pubmed]
  5. Tilmicosin does not inhibit interleukin-8 gene expression in the bovine lung experimentally infected with Mannheimia (Pasteurella) haemolytica. Goubau, S., Morck, D.W., Buret, A. Can. J. Vet. Res. (2000) [Pubmed]
  6. Analysis of tilmicosin in swine liver extracts by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Kiehl, D.E., Kennington, A.S. Rapid Commun. Mass Spectrom. (1995) [Pubmed]
  7. Induction of macrolide resistance in Mycoplasma gallisepticum in vitro and its resistance-related mutations within domain V of 23S rRNA. Wu, C.M., Wu, H., Ning, Y., Wang, J., Du, X., Shen, J. FEMS Microbiol. Lett. (2005) [Pubmed]
  8. Postantibiotic effects and postantibiotic sub-MIC effects of erythromycin, roxithromycin, tilmicosin, and tylosin on Pasteurella multocida. Lim, J., Yun, H. Int. J. Antimicrob. Agents (2001) [Pubmed]
  9. Comparison of in vitro activity of danofloxacin, florfenicol, oxytetracycline, spectinomycin and tilmicosin against recent field isolates of Mycoplasma bovis. Ayling, R.D., Baker, S.E., Peek, M.L., Simon, A.J., Nicholas, R.A. Vet. Rec. (2000) [Pubmed]
  10. Postantibiotic and physiological effects of tilmicosin, tylosin, and apramycin at subminimal and suprainhibitory concentrations on some swine and bovine respiratory tract pathogens. Diarra, M.S., Malouin, F., Jacques, M. Int. J. Antimicrob. Agents (1999) [Pubmed]
  11. Effects of tilmicosin phosphate, administered prior to transport or at time of arrival, and feeding of chlortetracycline, after arrival in a feedlot, on Mannheimia haemolytica in nasal secretions of transported steers. Frank, G.H., Duff, G.C. Am. J. Vet. Res. (2000) [Pubmed]
  12. Pharmacokinetics of tilmicosin after oral administration in swine. Shen, J., Li, C., Jiang, H., Zhang, S., Guo, P., Ding, S., Li, X. Am. J. Vet. Res. (2005) [Pubmed]
  13. Minimum inhibitory concentration breakpoints and disk diffusion inhibitory zone interpretive criteria for tilmicosin susceptibility testing against Pasteurella multocida and Actinobacillus pleuropneumoniae associated with porcine respiratory disease. Shryock, T.R., Staples, J.M., DeRosa, D.C. J. Vet. Diagn. Invest. (2002) [Pubmed]
  14. Intracellular accumulation, subcellular distribution, and efflux of tilmicosin in chicken phagocytes. Scorneaux, B., Shryock, T.R. Poult. Sci. (1998) [Pubmed]
  15. Production and characterization of monoclonal antibodies against the antibiotic tilmicosin. Beier, R.C., Creemer, L.C., Ziprin, R.L., Nisbet, D.J. J. Agric. Food Chem. (2005) [Pubmed]
  16. Synthesis, antimicrobial activity and in vivo fluorine NMR of a hexafluorinated derivative of tilmicosin. Creemer, L.C., Kirst, H.A., Shryock, T.R., Campbell, J.B., Webb, A.G. J. Antibiot. (1995) [Pubmed]
  17. Effect of tilmicosin on chemotactic, phagocytic, and bactericidal activities of bovine and porcine alveolar macrophages. Brumbaugh, G.W., Herman, J.D., Clancy, J.S., Burden, K.I., Barry, T., Simpson, R.B., López, H.S. Am. J. Vet. Res. (2002) [Pubmed]
  18. Intracellular accumulation, subcellular distribution, and efflux of tilmicosin in bovine mammary, blood, and lung cells. Scorneaux, B., Shryock, T.R. J. Dairy Sci. (1999) [Pubmed]
  19. Effect of bentonite incorporated in a feed ration with tilmicosin in the prevention of induced Mycoplasma gallisepticum airsacculitis in broiler chickens. Shryock, T.R., Klink, P.R., Readnour, R.S., Tonkinson, L.V. Avian Dis. (1994) [Pubmed]
  20. Public health consequences of macrolide use in food animals: a deterministic risk assessment. Hurd, H.S., Doores, S., Hayes, D., Mathew, A., Maurer, J., Silley, P., Singer, R.S., Jones, R.N. J. Food Prot. (2004) [Pubmed]
  21. Efficacy of danofloxacin in the treatment of respiratory disease in European cattle. Rowan, T.G., Sarasola, P., Sunderland, S.J., Giles, C.J., Smith, D.G. Vet. Rec. (2004) [Pubmed]
  22. Long-acting antibiotic formulations in the treatment of calf pneumonia: a comparative study of tilmicosin and oxytetracycline. Laven, R., Andrews, A.H. Vet. Rec. (1991) [Pubmed]
  23. Tilmicosin and tylosin have anti-inflammatory properties via modulation of COX-2 and iNOS gene expression and production of cytokines in LPS-induced macrophages and monocytes. Cao, X.Y., Dong, M., Shen, J.Z., Wu, B.B., Wu, C.M., Du, X.D., Wang, Z., Qi, Y.T., Li, B.Y. Int. J. Antimicrob. Agents (2006) [Pubmed]
  24. In vitro complex formation and inhibition of hepatic cytochrome P450 activity by different macrolides and tiamulin in goats and cattle. Zweers-Zeilmaker, W.M., Van Miert, A.S., Horbach, G.J., Witkamp, R.F. Res. Vet. Sci. (1999) [Pubmed]
  25. Tilmicosin-induced bovine neutrophil apoptosis is cell-specific and downregulates spontaneous LTB4 synthesis without increasing Fas expression. Lee, W.D., Flynn, A.N., LeBlanc, J.M., Merrill, J.K., Dick, P., Morck, D.W., Buret, A.G. Vet. Res. (2004) [Pubmed]
  26. Anti-inflammatory benefits of tilmicosin in calves with Pasteurella haemolytica-infected lungs. Chin, A.C., Morck, D.W., Merrill, J.K., Ceri, H., Olson, M.E., Read, R.R., Dick, P., Buret, A.G. Am. J. Vet. Res. (1998) [Pubmed]
  27. Single-dose treatment of neonatal calf pneumonia with the new macrolide antibiotic tilmicosin. Ose, E.E., Tonkinson, L.V. Vet. Rec. (1988) [Pubmed]
  28. Comparison of tilmicosin with long-acting oxytetracycline for treatment of respiratory tract disease in calves. Musser, J., Mechor, G.D., Gröhn, Y.T., Dubovi, E.J., Shin, S. J. Am. Vet. Med. Assoc. (1996) [Pubmed]
  29. In vitro susceptibility of porcine respiratory pathogens to tilmicosin. DeRosa, D.C., Veenhuizen, M.F., Bade, D.J., Shryock, T.R. J. Vet. Diagn. Invest. (2000) [Pubmed]
WikiGenes - Universities